Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19

Journal of Medical Virology - Tập 92 Số 10 - Trang 2227-2231 - 2020
Anália do Carmo1, João Luiz Pereira Vaz1, Vanda Mota1, Alexandra Mendes1, Catarina M. Morais1, Andreia Coelho da Silva1, Elisabete Camilo1, Catarina Silva Pinto2, Elizabete Cunha2, Janet Pereira2, Margarida Coucelo3,3, P. Martinho2, Lurdes Correia1, Gilberto Marques1, Lucília Araújo1, Fernando Rodrigues1
1Laboratory of Molecular Biology/Virology, Clinical Pathology Unit Centro Hospitalar e Universitário de Coimbra Coimbra Portugal
2Molecular Hematology Laboratory, Department of Clinical Hematology Centro Hospitalar e Universitário de Coimbra Coimbra Portugal
3Group of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine of University of Coimbra (FMUC), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal

Tóm tắt

AbstractPatients with coronavirus disease‐2019 may be discharged based on clinical resolution of symptoms, and evidence for viral RNA clearance from the upper respiratory tract. Understanding the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral clearance profile is crucial to establish a re‐testing plan on discharge and ending isolation of patients. We aimed to evaluate the number of days that a patient needed to achieve undetectable levels of SARS‐CoV‐2 in upper respiratory tract specimens (nasopharyngeal swab and/or an oropharyngeal swab). The clearance and persistence of viral RNA was evaluated in two groups of positive patients: those who achieved two negative reverse transcription‐polymerase chain reaction (RT‐PCR) tests and those who kept testing positive. Patients were organized thereafter in two subgroups, mild illness patients discharged home and inpatients who had moderate to severe illness. Results from RT‐PCR tests were then correlated with results from the evaluation of the immune response. The study evidenced that most patients tested positive for more than 2 weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead.

Từ khóa


Tài liệu tham khảo

10.1097/CM9.0000000000000774

European Centre for Disease Prevention and Control.Guidance for discharge and ending isolation in the context of widespread community transmission of COVID‐19—First Update Target Audience Scientific Evidence on SARS‐CoV‐2 Shedding.2020.

10.1016/S0140-6736(20)30251-8

10.1016/j.cmi.2020.04.023

Wölfel R, 2020, Virological assessment of hospitalized patients with COVID‐2019, Nat Res., 581, 1

10.1038/s41591-020-0869-5

CDC/DDID/NCIRD/Division of Viral Diseases.Real‐time RT‐PCR diagnostic panel for emergency use only. CDC‐006‐00019 revision:03;2020.

Padoan A, 2020, Analytical performances of a chemiluminescence immunoassay for SARS‐CoV‐2 IgM/IgG and antibody kinetics, Clin Chem Lab Med, 1399

10.1515/cclm-2020-0473

10.1016/S2468-1253(20)30083-2

10.1038/s41577-020-0311-8

Zhang G, 2020, Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019, J Infect Dis, 1

10.1016/S0140-6736(20)30566-3

Wang‐Da Liu, 2020, Prolonged virus shedding even after seroconversion in a patient with COVID‐19, J Infect.

Du Z, 2020, Detection of antibodies against SARS ‐ CoV ‐ 2 in patients with, J Med Virol, 57, 1

Hu Q, 2020, The production and clinical implications of SARS‐CoV‐2 antibodies The production and clinical implications of SARS‐CoV‐2 antibodies, medRxiv

HouH WangT ZhangB et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019.Clin Transl Immunol.2020;9:e1136.https://doi.org/10.1002/cti2.1136

10.1016/S1473-3099(20)30232-2

10.1378/chest.129.1.12

Thông tin
Thông tin xuất bản

Journal of Medical Virology

Tập 92 Số 10

2227-2231

Thông tin tác giả